Research Categories
- Anesthesia
- Arthroscopy
- Biologics/Biomaterials
- Cancer Devices
- Cardiovascular
- Cosmetic Devices
- Dental
- Diabetes
- Diagnostics
- Dialysis
- Drug Delivery
- Ear, Nose, Throat
- Endoscopy
- Gastrointestinal (GI)
- General Surgery
- Gynecology Devices
- Healthcare IT
- Hearing Devices
- Imaging
- Immunology
- Infusion Therapy
- Laparoscopy
- Minimally Invasive Surgery
- Neurology Devices
- Oncology
- Operating Room Equipment
- Ophthalmics Devices
- Orthopedics
- Patient Monitoring
- Peripheral Vascular
- Respiratory Devices
- Robotics & Navigation
- Sleep Apnea & Diagnostics
- Spine
- Stents
- Telehealth & Telemedicine
- Tissue Repair
- Urology
- Vascular Access
- Video Hi-Tech
- Women's Health
- Wound Care
Immunology
Showing 13–24 of 29 results
Rheumatoid Arthritis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis outside the U.S. and Europe, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Psoriasis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat psoriasis outside the U.S. and Europe, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Crohn’s Disease Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat Crohn’s disease outside the U.S. and Europe, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ankylosing Spondylitis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis outside the U.S. and Europe, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Immunology Drugs Market Overview | United States | 2018-2024 | MedView
The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. The reports covers second line treatments, their dosage, comparative cost studies, market size and revenue forecasts.
more...
Ulcerative Colitis Drug Market Analysis | United States | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ulcerative colitis in the US, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Rheumatoid Arthritis Drug Market Analysis | United States | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis in the US, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Psoriasis Drug Market Analysis | United States | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat psoriasis in the US, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Crohn’s Disease Drug Market Analysis | United States | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat Crohn’s disease in the US, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ankylosing Spondylitis Drug Market Analysis | United States | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis in the US, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Crohn’s Disease Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat Crohn’s disease in Europe, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...